Iceland· IS-EU/1/21/1576/001
Brukinsa
A zanubrutinib product containing zanubrutinibum inn, registered in Iceland by Beone Medicines Ireland Limited. The same ATC class is registered in 15 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Zanubrutinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EL03 (zanubrutinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Zanubrutinib · ATC L01EL03
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of zanubrutinib costs, country by country.
Normalised to the WHO defined daily dose (0.32 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Zanubrutinib · price per daily dose (0.32 g)
USD · FX 28 Sept 2026
- CH Switzerland$188.14
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Zanubrutinibum INN
- Manufacturer
- Beone Medicines Ireland Limited
- Country
- Iceland (IS)
- ATC code
- L01EL03
- ATC class
- Zanubrutinib
- Defined daily dose
- 0.32 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean395878120 stk x1 glasISK 759607
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
217 interactions on record for zanubrutinib.
Graded by severity as the source publishes them — 140 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Zanubrutinib · interactions on record
217 records
- 140 severe
- 77 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Zanubrutinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBRUKINSABeOne Medicines USA, Inc.
- SpainBRUKINSA 80 MG CAPSULAS DURASBeone Medicines Ireland Limited
- SwitzerlandBrukinsa
- CzechiaBRUKINSABeOne Medicines Ireland Limited, Dublin
- FinlandBRUKINSABeOne Medicines Ireland Limited
- FranceBRUKINSA 80 mg, géluleBEONE MEDICINES IRELAND (IRLANDE)
- BelgiumBrukinsa 80 mgBeOne Medicines Ireland
- IrelandBRUKINSA 80 mg hard capsulesBeiGene Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Norway · Brukinsa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f5a3b367-8bb6-4ec4-8ef1-a9dbd4ae5b16 GET /v1/drugs/f5a3b367-8bb6-4ec4-8ef1-a9dbd4ae5b16?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Hart hylki",
"source": "lyfjastofnun",
"atc_raw": "L01EL03",
"marketed": true,
"strength": "80 mg",
"ma_number": "EU/1/21/1576/001",
"substance": "Zanubrutinibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum og krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44522"
}See everything about zanubrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.